Farfel Gail M
Known title: Chief Executive OfficerCIK: 0001614780
Farfel Gail M's purchase track record
Farfel Gail M has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/14/2022 | PMN | $5K | -3.1% | +1.9% | +9.4% |
| 12/6/2022 | PMN | $6K | -9.4% | -7.4% | +8.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PMN | ▲ Buy | Grant | 53,192 | — | 8/23/2023 | View on chart |
| PMN | ▲ Buy | Open Market | 1,000 | $5K | 12/14/2022 | View on chart |
| PMN | ▲ Buy | Open Market | 1,000 | $6K | 12/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer
ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer. ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.